PPARA and cardiovascular disorder: Later trials with Aleglitazar, also a dual PPARα and γ agonist, had to be stopped due to excess adverse events, making this class of therapeutics unlikely to be successful in the treatment of cardiovascular disease in diabetic patients [38].